Retatrutide side effects

In the published retatrutide trials, the adverse events reported most often were gastrointestinal. The pattern is familiar across the entire GLP-1 class and is driven largely by the GLP-1 component's effect on gastric emptying and appetite:

These effects were generally described as mild to moderate and were clearly dose-dependent: more common at higher doses and during faster up-titration. For the precise incidence rates by dose, read the primary publication (see the trial-results article for the citation) rather than relying on summarised figures.

One effect distinguishes retatrutide from pure GLP-1 agonists like semaglutide: a transient increase in heart rate reported in the published Phase 2 trial. This is linked to retatrutide's glucagon-receptor activity — the third mechanism that single- and dual-agonist drugs do not have.

Because this is a mechanism-specific signal rather than a class effect, it is one of the more important things to understand about retatrutide specifically. The exact magnitude, dose-relationship and time-course should be read from the primary trial publication; this page flags the signal qualitatively rather than quoting a figure that should be verified against the source.

The standard lever for managing GLP-1-class side effects is slow, stepwise up-titration — beginning at a low dose and increasing gradually so the gastrointestinal system can adapt. Slower titration is consistently associated with fewer and milder GI effects.

The titration cadence used in the trials, and the rationale for it, is covered in the dosing guide. Note that this describes the trial approach for context only — it is not a recommendation to administer an unapproved compound.

Retatrutide is an investigational triple GLP-1/GIP/glucagon agonist. It is not approved by the MHRA (or any regulator) and is supplied strictly for in-vitro research — not for human use. This page is an educational summary, not medical advice.

• Long-term safety has not been established; trial data are of finite length and rare or delayed effects may not yet be characterised.
• The glucagon-receptor activity adds a transient heart-rate rise not seen with pure GLP-1 agonists — a retatrutide-specific consideration.
• This page does not assess individual risk factors (e.g. personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, gallbladder or severe gastrointestinal disease, pregnancy or breastfeeding) that a clinician would weigh before any GLP-1-class agent.
• Anyone considering a GLP-1 medicine for a health reason should speak to a doctor or pharmacist about an approved, prescribed option.

For the regulatory context behind the unapproved status, see Is Retatrutide Legal in the UK?

What are the most common retatrutide side effects?

Across the published trials the most commonly reported adverse events were gastrointestinal: nausea, diarrhoea, vomiting and constipation. These were generally dose-dependent — more frequent at higher doses and during faster up-titration — and most were reported as mild to moderate.

Does retatrutide raise heart rate?

The published Phase 2 trial reported a transient increase in heart rate, a signal linked to retatrutide's glucagon-receptor activity that is not seen with pure GLP-1 agonists. The exact magnitude and time-course should be read from the primary publication rather than assumed.

How are retatrutide side effects managed in trials?

The standard approach across the GLP-1 class is slow, stepwise up-titration: starting at a low dose and increasing every few weeks so the gastrointestinal system can adapt. Slower titration is consistently associated with better tolerability.

Is retatrutide's safety fully established?

No. Retatrutide is investigational and its long-term safety has not been established. The available data come from clinical trials of finite length; rare or long-term effects may not yet be characterised. It is not approved for human use.